Methyllycaconitine

Overview

Methyllycaconitine (MLA) is a blood-brain barrier-permeable antagonist of α7 nicotinic acetylcholine receptor ( α7nAChR ) with an IC 50 of 2 nM. Methyllycaconitine inhibits Aβ 25-35 -induced autophagy by restoring the mTOR pathway, and prevents reactive oxygen species ( ROS ) production, microglial activation, reduced dopamine uptake, loss of dopaminergic terminals and catecholamine secretion. Methyllycaconitine induces hippocampal glutamate efflux, enhances long-term potentiation, and improves memory acquisition. Methyllycaconitine can be used in research related to Alzheimer's disease, cerebral palsy, Parkinson's disease and schizophrenia.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Alzheimer's Disease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Reactive Oxygen Species (ROS) | Products > Signaling Pathways > mTOR | Products > Signaling Pathways > nAChR

Product Information

• Catalog No.: HY-N2332
• CAS No.: 21019-30-7
• Molecular Formula: C37H50N2O10
• Molecular Weight: 682.80
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source